Levine et al. examined 224 IBD patients on GLP-1 receptor agonists and found no significant change (p = 0.36) in the rates of IBD exacerbation (measured as a composite of IBD-related hospitalizations, steroid prescriptions, medication escalation or adjustments, or IBD-related surgeries) after 12 months of GLP-1 RA therapy, compared to the 12 months prior to treatment [36]. This evidence concerns the gene GLP1R and rheumatoid arthritis.